Search Results
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms." In light of the trial results, Insmed decided to discontinue development of brensocatib. On this news, Insmed's stock price
More news about: Pomerantz LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement. Furthermore, the study did not meet its
More news about: Pomerantz LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement. Furthermore, the study did not meet its
More news about: Pomerantz LLP
Jan 15, 2026, 08:59 ET aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement
Pablo Jiménez Martínez and his team in Spain, examined 50 trained CrossFit® athletes (25 male, 25 female). The results demonstrate that a single 2.5 mg dose of aXivite® delivers significant physiological advantages:Superior Mechanical Output: Supplemented athletes achieved higher
More news about: aXichem AB
Jan 15, 2026, 08:55 ET aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement
Pablo Jiménez Martínez and his team in Spain, examined 50 trained CrossFit® athletes (25 male, 25 female). The results demonstrate that a single 2.5 mg dose of aXivite® delivers significant physiological advantages:Superior Mechanical Output: Supplemented athletes achieved higher
More news about: aXichem AB
Jan 15, 2026, 08:30 ET Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
trials."The study used positron emission tomography (PET) imaging to evaluate VMAT2 TO following single doses of either INGREZZA (40 mg or 80 mg) or AUSTEDO XR (24 mg or 48 mg) in eight participants, each completing four PET visits. Using a linear mixed-effects model, the primary TO analysis demonstrated
More news about: Neurocrine Biosciences, Inc.
Jan 14, 2026, 16:30 ET TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing
More news about: Johnson & Johnson
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
with various RAS mutations during dose escalation. The potential best-in-class pan-RAS molecular glue achieved ongoing responses at doses as low as 8 mg once daily, with two confirmed PRs and one unconfirmed PR observed at this dose level."With both ERAS-0015 and ERAS-4001 INDs previously cleared
More news about: Equity Insider
Jan 14, 2026, 09:15 ET TheraTears® Expands Dry Eye Portfolio with Two New Innovations: Eyelid Cleansing Wipes and Dry & Tired Preservative Free Lubricant Eye Drops
blend of OxyLytes™, the five vital electrolytes (Sodium Na+, Potassium K+, Calcium Ca2+, Magnesium Mg2+, Bicarbonate HCO3-) found in natural tears. The EXTRA formula offers up to 12 hours of hydrating comfort. Available
More news about: TheraTears®
Jan 14, 2026, 09:02 ET DripDrop® Hydration Launches Breakthrough Zero Sugar Plus - The Complete Zero Sugar Hydration
Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.†3X the sodium electrolytes (660mg, 216mg) per 16oz vs leading sports drink.*Versus DripDrop Zero Sugar
More news about: DripDrop
Jan 14, 2026, 09:00 ET Circle K Becomes First Major Convenience Chain in Texas to Sell THC Beverages, Launching With VARIN
the cold box at Circle K makes choosing that kind of experience as easy as grabbing your favorite beverage."Consumers can choose between 10 mg and 30 mg THC options across four bold, flavor-forward varieties: Appleberry Rosehip, Blue Razz Bombsicle, Pink Strawburst and Coconut Wave. With zero sugar,
More news about: VARIN
Jan 14, 2026, 07:30 ET Keenova to Demonstrate Live Dupuytren's Contracture Treatment Procedure During American Association for Hand Surgery Meeting
patients taking low-dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration
More news about: Keenova Therapeutics
Jan 13, 2026, 16:45 ET Keenova Announces New Dupuytren's Contracture Survey Presentation About Patient Perceptions and Treatment Outcomes
patients taking low-dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration
More news about: Keenova Therapeutics
Jan 13, 2026, 12:53 ET Lawmakers and Advocates urge Maryland to enact essential water quality management reforms to prevent spread of Legionella and Legionnaires' Disease
include:Public Water System Requirements:Maintain minimum detectable disinfectant levels (0.5 mg/L for chlorine; 1.0 mg/L for chloramine).Develop a distribution system maintenance plan to mitigate the risk of Legionella bacteria.
More news about: Prevent Legionnaires'
Jan 13, 2026, 10:03 ET Odyssey Functional Energy Officially Unveils Unified Brand Identity as It Enters Its Next Era
consumers flexibility based on lifestyle and performance needs:The 222mg caffeine line: Pineapple Mango, Blue Raspberry, Pink Lemonade, and Strawberry Watermelon.The 85mg caffeine line: Dragon Fruit Lemonade, Tropical Breeze, Passion Fruit Guava, Blackberry Lemonade,
More news about: Odyssey Functional Energy
Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
www.fda.gov/medwatch.CAPLYTA is available in 42 mg, 21 mg, and 10.5 mg capsules.US-CAP-2500827Please see full
More news about: Johnson & Johnson
Jan 13, 2026, 08:00 ET Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
stair-climb, while identifying a dose of 10 mg to evaluate in Phase 3.Reported initial results from the FOX Phase 2 placebo-controlled trial in participants with Duchenne previously treated with gene therapy that also supported that sevasemten 10 mg has the potential to reduce the rate of functional
More news about: Edgewise Therapeutics
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
clinically meaningful reductions in seizure frequency compared to pretreatment baseline. Specifically, the majority of participants treated with opakalim 75 mg once daily who completed at least 6 months of OLE treatment showed ≥50% reductions in seizure frequency compared to pretreatment baseline.Well-tolerated
More news about: Biohaven Ltd.
Jan 12, 2026, 10:35 ET Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
mutations and the potential to become a cornerstone therapy across the EGFR mutant spectrum."The randomized Phase 3 study evaluates firmonertinib 240 mg once daily versus the investigator's choice of osimertinib or afatinib in first-line patients with EGFR PACC mutant NSCLC. Firmonertinib was granted
More news about: USA News Group
Jan 12, 2026, 09:52 ET GNC Reinvents Creatine for 2026, From Its Classic Monohydrate to Next-Generation Muscle-Building Systems
creatine phosphate – a muscle-ready form of creatine that plays a direct role in producing quick energy for explosive efforts50 mg AstraGin® and 200 mg sodium – to help facilitate creatine absorption and uptake into muscle cellsBy combining creatine phosphate, MonoPhate helps
More news about: GNC
Jan 12, 2026, 08:05 ET Rigel Provides Business Update and 2026 Outlook
generally well tolerated. RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose groupEnrollment in the dose expansion phase of the Phase 1b study is ongoing and Rigel is on track to complete
More news about: Rigel Pharmaceuticals, Inc.
Jan 12, 2026, 08:00 ET Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease
of tegoprazan 50mg and 100mg versus placebo over 4 weeks. The Phase 3 EE study (NCT05587309) was a large, multi-center, double-blind study (n=1,250, including 463 patients with LA Grade C and D esophagitis) evaluating the safety and efficacy of tegoprazan 100mg versus lansoprazole 30mg. The study consisted
More news about: Sebela Pharmaceuticals
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
diabetes who have obesity or are overweight. Patients in both trials are being randomized to one of four weekly treatment arms: VK2735 7.5 mg; VK2735 12.5 mg; VK2735 17.5 mg; and placebo.Additionally, the company recently announced the completion of enrollment in an exploratory maintenance dosing study
More news about: Viking Therapeutics, Inc.
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
NCT04562389) with 353 patients in early September 2025. SENTRY is evaluating 60 mg once-weekly selinexor in combination with ruxolitinib compared to ruxolitinib plus placebo. The preliminary baseline characteristics for patients enrolled
More news about: Karyopharm Therapeutics Inc.
Jan 12, 2026, 07:00 ET Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
Medical College Hospital and Chinese Academy of Medical Sciences, and enrolled a total of 430 patients, who were randomized 1:1 to receive zemprocitinib 12 mg twice daily or placebo (PBO) twice daily. The primary endpoint was the proportion of patients achieving an ACR20 response at Week 24, with key secondary
More news about: Lynk Pharmaceuticals Co., Ltd.